Citadel Advisors’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-4,100
| Closed | -$7.17K | – | 14666 |
|
|
2025
Q1 | $7.17K | Sell |
4,100
-2,900
| -41% | -$3.83K | ﹤0.01% | 13701 |
|
|
2024
Q4 | $11.1K | Sell |
7,000
-2,300
| -25% | -$3.53K | ﹤0.01% | 13571 |
|
|
2024
Q3 | $14.6K | Buy |
9,300
+1,100
| +13% | +$1.82K | ﹤0.01% | 13015 |
|
|
2024
Q2 | $14.6K | Sell |
8,200
-4,400
| -35% | -$10.2K | ﹤0.01% | 12868 |
|
|
2024
Q1 | $36.3K | Buy |
12,600
+10,500
| +500% | +$17.1K | ﹤0.01% | 12495 |
|
|
2023
Q4 | $2.69K | Buy |
2,100
+2,000
| +2,000% | +$2.66K | ﹤0.01% | 13670 |
|
|
2023
Q3 | $138 | Hold |
100
| – | – | ﹤0.01% | 14154 |
|
|
2023
Q2 | $147 | Buy |
+100
| New | +$133 | ﹤0.01% | 14204 |
|
|
2023
Q1 | – | Sell |
-1,300
| Closed | -$1.78K | – | 15387 |
|
|
2022
Q4 | $1.78K | Buy |
+1,300
| New | +$2.04K | ﹤0.01% | 14416 |
|
|
2021
Q4 | – | Sell |
-2,790
| Closed | -$19K | – | 14594 |
|
|
2021
Q3 | $19K | Sell |
2,790
-3,270
| -54% | -$24K | ﹤0.01% | 13646 |
|
|
2021
Q2 | $49K | Buy |
6,060
+4,410
| +267% | +$49.2K | ﹤0.01% | 13348 |
|
|
2021
Q1 | $26K | Buy |
+1,650
| New | +$24.4K | ﹤0.01% | 13051 |
|
|
2017
Q3 | – | Sell |
-98
| Closed | -$12K | – | 7953 |
|
|
2017
Q2 | $12K | Sell |
98
-170
| -63% | -$28.4K | ﹤0.01% | 7363 |
|
|
2017
Q1 | $53K | Buy |
268
+179
| +201% | +$34.1K | ﹤0.01% | 7032 |
|
|
2016
Q4 | $24K | Buy |
+89
| New | +$28.9K | ﹤0.01% | 7043 |
|
|
2016
Q3 | – | Sell |
-203
| Closed | -$71K | – | 7670 |
|
|
2016
Q2 | $71K | Buy |
203
+29
| +17% | +$20.8K | ﹤0.01% | 6318 |
|
|
2016
Q1 | $145K | Buy |
174
+126
| +263% | +$100K | ﹤0.01% | 5849 |
|
|
2015
Q4 | $51K | Sell |
48
-88
| -65% | -$88.2K | ﹤0.01% | 7295 |
|
|
2015
Q3 | $107K | Sell |
136
-13
| -9% | -$13.3K | ﹤0.01% | 6893 |
|
|
2015
Q2 | $196K | Buy |
149
+133
| +831% | +$215K | ﹤0.01% | 6352 |
|
|
2015
Q1 | $32K | Sell |
16
-24
| -60% | -$52.2K | ﹤0.01% | 7660 |
|
|
2014
Q4 | $77K | Buy |
+40
| New | +$71.1K | ﹤0.01% | 6872 |
|
Other funds holding RGLS
Citadel Advisors's RGLS Position: Q2 2025 in Review
Citadel Advisors sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 148,280 shares — an estimated $259K sold.
Citadel Advisors first reported a position in RGLS in Q4 2014 and held it in 24 quarters. The position peaked at $776K in Q1 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Citadel Advisors reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 148,280 Regulus Therapeutics shares in Q2 2025, an estimated $259K.
- Citadel Advisors first reported a position in Regulus Therapeutics in Q4 2014 and held it in 24 quarters.
- Citadel Advisors's Regulus Therapeutics position peaked at $776K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.